Mont-Saint-Guibert, Belgium – 17 December 2021 – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that it has received a transparency notification dated December 17, 2021 indicating that Tolefi SA and related persons have crossed together the statutory threshold of 20%, holding 18,65% of the voting rights of the company as of 8 December 2021.
Content of the Notification:
- Reason of the Notification:
Downward passive crossing of the 20% threshold
Downward passive crossing by persons acting in concert
- Notification by:
Persons acting in concert
- Persons subject to the notification requirement:
Tolefi SA, Chaussée de Waterloo 1589D, 1180 Uccle
- Transaction date
December 8, 2021
- Threshold that is crossed (in %)
- Notified details:
|A) Voting Rights||Previous notification||After the Transaction|
|#of voting rights||# of voting rights||% of voting rights|
|Holders of voting rights||Linked to the securities||Not linked to the securities||Linked to the securities||Not linked to the securities|
Tolefi SA is 100% controlled by Serge Goblet, Isabelle Thoumyre, Jérôme and Jean-Daniel Goblet.
- The Press Release may be consulted on the website of Celyad Oncology via this link.
The notification can be consulted on the website if Celyad Oncology via this link.
- Contact person(s):
By law, any transparency declaration must be sent to our Company by email to the attention of Filippo Petti, Chief Executive Officer (CEO): firstname.lastname@example.org.